| Outcome Measures: |
Primary: Change in laboratory measured glycated haemoglobin (HbA1c) (% point), % point, From baseline (week -12 to 0) to end of study (week 26-36)|Change in laboratory measured HbA1c (mmol/mol), mmol/mol, From baseline (week -12 to 0) to end of study (week 26-36) | Secondary: Change in laboratory measured fasting plasma glucose (FPG), mg/dL, From baseline (week -12 to 0) to end of study (week 26-36)|Change in laboratory measured FPG, mmol/L, From baseline (week -12 to 0) to end of study (week 26-36)|Change in daily insulin doses (basal insulin), units/day, From baseline (week -12 to 0) to end of study (week 26-36)|Change in daily insulin doses (prandial insulin), units/day, From baseline (week -12 to 0) to end of study (week 26-36)|Change in daily insulin doses (total insulin), units/day, From baseline (week -12 to 0) to end of study (week 26-36)|Change in number of patient reported overall non-severe hypoglycaemic episodes, Number of episodes, Pre and Post- initiation of treatment with Tresiba®. Episodes occurring within 4 weeks prior to initiation of treatment with Tresiba® (week -12 to 0) and within 4 weeks prior to end of study (week 26 to 36)|Change in number of patient reported nocturnal non-severe hypoglycaemic episodes, Number of episodes, Pre and Post- initiation of treatment with Tresiba®. Episodes occurring within 4 weeks prior to initiation of treatment with Tresiba® (week -12 to 0) and within 4 weeks prior to end of study (week 26 to 36)|Change in number of patient reported severe hypoglycaemic episodes (overall), Number of episodes, Pre and Post- initiation of treatment with Tresiba®. Episodes occurring within 4 weeks prior to initiation of treatment with Tresiba® (week -12 to 0) and within 4 weeks prior to end of study (week 26 to 36)|Reason(s) for discontinuing treatment with Tresiba® during the treatment period, if applicable (according to pre-specified response options), Number of participants per response option, After initiation of treatment with Tresiba® (week 0) until treatment discontinuation (week 26-36)
|
| Locations: |
Novo Nordisk Investigational Site, Alushta, 298500, Russian Federation|Novo Nordisk Investigational Site, Belogorsk, 297600, Russian Federation|Novo Nordisk Investigational Site, Bryansk, 242610, Russian Federation|Novo Nordisk Investigational Site, Chapaevsk, 446100, Russian Federation|Novo Nordisk Investigational Site, Chelyabinsk, 454048, Russian Federation|Novo Nordisk Investigational Site, Dyurtyuli, 452320, Russian Federation|Novo Nordisk Investigational Site, Elista, 358000, Russian Federation|Novo Nordisk Investigational Site, Ivanovo, 153012, Russian Federation|Novo Nordisk Investigational Site, Kaluga, 248002, Russian Federation|Novo Nordisk Investigational Site, Kazan, 420073, Russian Federation|Novo Nordisk Investigational Site, Krasnodar, 350000, Russian Federation|Novo Nordisk Investigational Site, Krasnoyarsk, 660021, Russian Federation|Novo Nordisk Investigational Site, Krasnoyarsk, 660062, Russian Federation|Novo Nordisk Investigational Site, Lipetsk, 398043, Russian Federation|Novo Nordisk Investigational Site, Lyskovo, 606210, Russian Federation|Novo Nordisk Investigational Site, Magnitogorsk, 455016, Russian Federation|Novo Nordisk Investigational Site, Moscow Region, Dolgoprudny, 141707, Russian Federation|Novo Nordisk Investigational Site, Moscow, 111401, Russian Federation|Novo Nordisk Investigational Site, Moscow, 117036, Russian Federation|Novo Nordisk Investigational Site, Moscow, 129226, Russian Federation|Novo Nordisk Investigational Site, N. Novgorod, 603155, Russian Federation|Novo Nordisk Investigational Site, Odintsovo, Moscow Region, 143003, Russian Federation|Novo Nordisk Investigational Site, Penza, 440039, Russian Federation|Novo Nordisk Investigational Site, Penza, 440066, Russian Federation|Novo Nordisk Investigational Site, Rostov-on-Don, 344004, Russian Federation|Novo Nordisk Investigational Site, Saint-Peterburg, 195256, Russian Federation|Novo Nordisk Investigational Site, Saint-Peterburg, 199004, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 194358, Russian Federation|Novo Nordisk Investigational Site, Samara, 443111, Russian Federation|Novo Nordisk Investigational Site, Saratov, 410005, Russian Federation|Novo Nordisk Investigational Site, Saratov, 410033, Russian Federation|Novo Nordisk Investigational Site, Sergiev Posad, 141300, Russian Federation|Novo Nordisk Investigational Site, Sevastopol, 299011, Russian Federation|Novo Nordisk Investigational Site, Sovetskiy, 297200, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, 193231, Russian Federation|Novo Nordisk Investigational Site, Syktyvkar, 167981, Russian Federation|Novo Nordisk Investigational Site, Tula, 300035, Russian Federation|Novo Nordisk Investigational Site, Ufa, 450038, Russian Federation|Novo Nordisk Investigational Site, Voskresensk, 140203, Russian Federation|Novo Nordisk Investigational Site, Vyksa, 607060, Russian Federation
|
